DCM Shriram Fine Chemicals Ltd
DCM Shriram Ltd is a producer
of Pharmaceutical Intermediates,
particularly in the Anti-Infective
segment using Optical Isomer
separation as its core competence.[1]
- Market Cap ₹ 211 Cr.
- Current Price ₹ 24.3
- High / Low ₹ 52.5 / 17.3
- Stock P/E
- Book Value ₹ 24.1
- Dividend Yield 1.65 %
- ROCE 0.74 %
- ROE -0.29 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Stock is trading at 1.01 times its book value
Cons
- Company has low interest coverage ratio.
- Earnings include an other income of Rs.6.00 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| 429 | 386 | 371 | |
| Sales growth | -10% | -8% | |
| 396 | 379 | 369 | |
| Operating Profit | 33 | 7 | 1 |
| OPM % | 8% | 1.8% | 0.4% |
| 4 | -0 | 6 | |
| Interest | 2 | 1 | 2 |
| Depreciation | 9 | 8 | 8 |
| Profit before tax | 26 | -3 | -3 |
| Tax % | 26% | 13% | |
| 19 | -4 | -3 | |
| EPS in Rs | 1.92 | -0.41 | -0.32 |
| Dividend Payout % | 0% | -98% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -133% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|
| Equity Capital | 0.00 | 17 | 17 |
| Reserves | 215 | 194 | 192 |
| 13 | 13 | 15 | |
| 80 | 72 | 70 | |
| Total Liabilities | 308 | 295 | 295 |
| 130 | 103 | 99 | |
| CWIP | 0 | 0 | 6 |
| Investments | 23 | 33 | 21 |
| 155 | 159 | 168 | |
| Total Assets | 308 | 295 | 295 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 15 | 16 | |
| 0 | 11 | |
| -15 | -6 | |
| Net Cash Flow | 0 | 21 |
| Free Cash Flow | 12 | 35 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 73% | 294% |
Ratios
Consolidated / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 70 | 67 |
| Inventory Days | 74 | 64 |
| Days Payable | 80 | 78 |
| Cash Conversion Cycle | 65 | 53 |
| Working Capital Days | 52 | 46 |
| ROCE % | 1% |
Insights
In beta| Mar 2025 | Mar 2026 | |
|---|---|---|
| Export Revenue Share % ・Standalone data |
|
|
| R&D Expenditure INR Crore ・Standalone data |
||
| Revenue Share from Major Customers (≥10% of revenue) % ・Standalone data |
||
| Installed Production Capacity TPA ・Standalone data |
||
| Permanent Employees count ・Standalone data |
||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Copy of Newspaper Publication for Postal Ballot
-
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
- Postal ballot on Ashwini Shanker's 5-year independent director appointment and AoA alteration; e-voting Nov 22-Dec 21, 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper publication of Unaudited financial results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026
-
Intimation Regarding Change In The Corporate Office Of The Registrar And Share Transfer Agent (RTA) Of The Company
- KFin Technologies’ corporate office address changes effective December 1, 2026.
-
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
- Board approved Q2 FY27 results, appointed Ashwini Shanker as independent director, and proposed AOA changes.
Annual reports
-
Annual Report 2026
from bse